600079 人福医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,137,400-3.61%25,435,48424,524,74122,337,71920,548,930
减:营业总成本5,336,905-4.43%22,665,86821,417,05919,851,77518,750,613
    其中:营业成本3,157,244-7.49%14,103,26113,290,99212,615,13811,764,845
               财务费用66,934-16.80%350,704304,519236,944623,308
               资产减值损失1,33034.81%(393,861)(61,407)(88,312)(55,124)
公允价值变动收益(847)-87.04%112,717136,85543,4177,885
投资收益26,51457.16%133,086206,785835,557306,009
    其中:对联营企业和合营企业的投资收益23,54216.11%68,16159,99222,514132,336
营业利润857,3044.23%2,522,0293,447,1743,516,0282,249,040
利润总额827,4432.21%2,422,8303,383,8293,426,0532,172,974
减:所得税费用128,828-20.15%644,487568,563354,751354,782
净利润698,6157.78%1,778,3432,815,2663,071,3021,818,193
减:非控股权益158,270-2.18%448,598680,781587,194501,047
股东净利润540,34511.09%1,329,7452,134,4852,484,1091,317,146

市场价值指针
每股收益 (元) *0.33010.00%0.8201.3201.5400.830
每股派息 (元) *----0.4700.4600.1600.150
每股净资产 (元) *11.1103.61%10.79710.4419.2107.929
审计意见 #--带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见标准无保留意见标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容